UK region nears 100% LBC screening
This article was originally published in Clinica
285,000 (75%) of the 380,000 screens performed annually in the UK's West Midlands region of the NHS use liquid-based cytology (LBC). So said Hologic this week, reporting that nine of the region's 13 screening programmes have now converted from traditional Pap smear screening to LBC ThinPrep Pap Test, developed by Cytyc. "Substantial parts" of another two regions have also converted. The 13 programmes operate through 11 laboratories. All UK women aged 25-64 years are routinely invited for screening once every three years up to the age of 50, and then every five years. Cytyc became a wholly-owned subsidiary of Hologic in October 2007, in a $6.2bn merger (see Clinica No 1279, p 15).
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.